Sun, Feb 1, 2015, 12:48 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Osiris Therapeutics, Inc. Message Board

  • scistats scistats Jan 6, 2013 8:24 PM Flag

    Healthcare Costs Will Be $4.8 Trillion In 2021. Will Prochymal for AMI Reduce Heart Failure And Save Money?

    "Medicare spending alone will top $1 trillion in 2021, while total U.S. healthcare spending will balloon to $4.8 trillion." -Yahoo News

    "Heart failure (HF) ranks among the most costly chronic diseases in developed countries. At present these countries devote 1-2% of all healthcare expenditures towards HF. In the US, these costs are estimated at $US30.2 billion for 2007." -Duke University

    "Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart Attack" -Osiris Therapeutics

    When will the next round of Phase 2 Prochymal for AMI data be out, Oz? Daniel? Anyone? If Prochymal for AMI works, it will contribute to National debt reduction. The FDA will act accordingly.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The clamoring that I hear is from potential partners wanting to partner AMI with Osiris for Phase III. Our dreams fulfilled phase I.

      • 2 Replies to cimcbride
      • Osiris is accepting applications for product collaborations. The following partnerships are available: (1) one for foreign Prochymal/GvHD, (2) one for foreign Grafix, (3) one for local and foreign Ovation, (4) one for local and foreign Cartiform, (5) one for local and foreign Prochymal/AMI and (6) One for local and foreign Prochymal/Crohns.

        Upfront cash is needed to particpate plus 20% royalties on all future Sales. The list of possible candidates are shown below and are ordered in size by current revenue, highest to smallest. Pick 6 potential partners from the list below, but one large blockbuster deal will be considered as well as smaller companies in niche markets!

        Pfizer (with Wyeth)
        Johnson & Johnson
        Hoffmann–La Roche
        Novartis
        GlaxoSmithKline
        AstraZeneca
        Abbott Laboratories
        Merck & Co.
        Bristol-Myers Squibb
        Eli Lilly and Company
        Boehringer Ingelheim
        Takeda Pharmaceutical Co.
        Bayer [36]
        Amgen
        Genentech
        Baxter International
        Teva Pharmaceutical Industries
        Astellas Pharma
        Daiichi Sankyo
        Novo Nordisk
        Procter & Gamble
        Eisai
        Merck KGaA
        Alcon
        SINOPHARM
        Akzo Nobel
        UCB
        Nycomed
        Forest Laboratories
        Solvay
        Allergan
        Gilead Sciences
        CSL
        Chugai Pharmaceutical Co.
        Biogen Idec
        Bausch & Lomb
        Taiho Pharmaceutical Co.
        King Pharmaceuticals
        Watson Pharmaceuticals
        Mitsubishi Pharma
        Shire
        Cephalon
        Dainippon Sumitomo Pharma
        Kyowa Hakko
        Shionogi
        Mylan Laboratories
        H. Lundbeck

      • Wouldn't that embarrass Sanofi by highlighting to them that they just committed the biggest blunder of the century? Letting a little company like Osiris outwit the 6th largest Pharma in the world; that speaks volumes about about our little upstart Osiris. Well played Mr. Friedli and Dr. Mills.

        When billion dollar Pharmas become arrogant they lose! Sanofi's mistake will go down in the annuals of Pharma history as the biggest faux pas of the century.

 
OSIR
16.13-0.6900(-4.10%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.